Comparison
Semaglutide vs Tirzepatide
Reviewed by Marko Maal, MSc Pharmacy · University of Tartu · Pharmaceutical sciences — drug sourcing, formulation, regulatory review · Reviewed May 7, 2026
Reviewed for clinical and pharmacological accuracy by Marko Maal, MSc Pharmacy.
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Mean weight loss (68w) | 13.7% (SURMOUNT-5 head-to-head) | 20.2% (SURMOUNT-5 head-to-head) |
| CV outcomes data | SELECT — 20% MACE reduction | SURPASS-CVOT ongoing, results 2027 |
| OSA indication | No | Yes — Zepbound, Dec 2024 |
| Half-life | ~165 hours (weekly dosing) | ~120 hours (weekly dosing) |
| Routes | SC injection, oral (Rybelsus 7/14 mg) | SC injection only |
| Typical maintenance | 1.0–2.4 mg weekly (Wegovy) | 5–15 mg weekly (Zepbound) |
| List price / month | ~$1,350 (Wegovy) | ~$1,060 (Zepbound) |
| Most common AEs | Nausea (44%), diarrhea (30%), vomiting (24%) | Nausea (33%), diarrhea (23%), constipation (17%) |
How do they actually differ?
Evidence tier: 1 — mechanism and pharmacokinetics established by FDA-approval-grade RCT programs (STEP, SUSTAIN, SURMOUNT, SURPASS).
Semaglutide is a single-target GLP-1 receptor agonist; tirzepatide is a dual GLP-1 and GIP receptor agonist. Both are weekly subcutaneous injections, both work primarily through delayed gastric emptying, central appetite suppression, and glucose-dependent insulin release. The added GIP signaling on tirzepatide produces measurably greater weight loss, faster A1c reduction in T2D, and a slightly different gastrointestinal tolerability curve — most patients reach an effective dose with fewer titration steps. Semaglutide has the longer half-life (~165 hours) and a deeper outcomes-trial portfolio across cardiovascular, renal, and hepatic endpoints. Tirzepatide has the shorter half-life (~120 hours) but produces stronger reductions in body weight and waist circumference. Both share the same boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies, and the same general adverse-event profile dominated by nausea, vomiting, and diarrhea concentrated in the titration phase. Mechanistically they are not interchangeable: tirzepatide adds a pathway, it does not just amplify GLP-1 signaling. The comparisonMatrix has the dosing and pricing detail.
Who should choose semaglutide?
Evidence tier: 1 — SELECT trial established cardiovascular benefit in obesity without diabetes (Lincoff 2023), and FLOW established renal benefit in T2D with CKD.
Semaglutide is the better fit for patients whose primary clinical concern is cardiovascular protection rather than maximum weight loss. SELECT enrolled 17,604 patients with established cardiovascular disease and obesity but no diabetes, and showed a 20% reduction in major adverse cardiovascular events on semaglutide 2.4 mg weekly versus placebo. Wegovy now carries the FDA label for cardiovascular risk reduction in this population — tirzepatide does not, pending the SURPASS-CVOT readout in 2027. Semaglutide also has the longer track record in chronic kidney disease (Ozempic post-FLOW), in MASH (post-ESSENCE), and in older patients in general because it has been on the market longer. The oral formulation (Rybelsus) is unique to semaglutide — patients with severe needle aversion or who travel internationally where injectables are difficult may prefer the oral route despite its lower bioavailability. Patients already on Ozempic or Wegovy with adequate weight loss and good tolerability have no clinical reason to switch. Patients with a strong preference for the longer half-life and gentler titration curve also lean semaglutide. Discuss the trade-off between maximum weight loss and accumulated outcomes evidence with your physician.
Who should choose tirzepatide?
Evidence tier: 1 — SURMOUNT-5 directly demonstrated superior weight loss; SURPASS-2 demonstrated superior glycemic control versus semaglutide.
Tirzepatide is the better fit for patients whose primary goal is maximum weight loss, whose diabetes is poorly controlled on a GLP-1 monotherapy, or who carry an obstructive sleep apnea diagnosis. SURMOUNT-5 — the only head-to-head trial in obesity without T2D — produced a 20.2% mean weight loss on tirzepatide versus 13.7% on semaglutide at 72 weeks, with 65% of tirzepatide patients reaching 15% weight loss versus 32% of semaglutide patients. Discontinuation rates from gastrointestinal adverse events were actually lower on tirzepatide (2.7%) than on semaglutide (5.6%) in that trial. Zepbound is the only GLP-1-class agent FDA-approved for moderate-to-severe OSA in obesity (December 2024); semaglutide does not carry this indication. Patients who plateaued on semaglutide are also candidates for tirzepatide because the additional GIP pathway is mechanistically additive. The titration is also shorter to reach an effective range — clinicians often find this easier in practice. Patients with established cardiovascular disease without an obesity-driven indication should not default to tirzepatide while SURPASS-CVOT remains pending. Discuss the indication-versus-efficacy trade-off with your physician.
What does the evidence base actually say?
Evidence tier: 1 — multiple Phase 3 RCTs, one direct head-to-head in obesity (SURMOUNT-5), one in T2D (SURPASS-2), plus large cardiovascular outcomes trials.
The semaglutide evidence base began with the STEP program: STEP-1 produced 14.9% mean weight loss at 68 weeks in adults with obesity without diabetes. The class-defining cardiovascular outcomes trial is SELECT, which read out in 2023 with a 20% MACE reduction in 17,604 patients. The tirzepatide evidence base began with SURMOUNT-1, which produced 16-22.5% weight loss across 5/10/15 mg doses at 72 weeks. The two programs intersected directly twice: SURPASS-2 (T2D, 2021) showed tirzepatide superior to semaglutide 1 mg on both A1c and weight, and SURMOUNT-5 (2025) showed tirzepatide 10/15 mg superior to semaglutide 1.7/2.4 mg on weight loss in obesity without T2D. SURMOUNT-4 established that tirzepatide withdrawal produces substantial weight regain (14% gain on placebo vs 5.5% loss continuing) — the same pattern documented for semaglutide in STEP-4. Neither drug has 10-year safety data; both have the boxed C-cell warning. SURPASS-CVOT for tirzepatide is the next major readout in this class, expected 2027. Until then, the cardiovascular indication belongs to semaglutide.
Cost, access, and regulatory comparison
Evidence tier: 2 — pricing and access reflect April 2026 US-market reality and are subject to change.
Branded retail in the US runs ~$1,350/month for Wegovy and ~$1,060/month for Zepbound at full list price — Lilly's direct-pay program brought tirzepatide pricing below semaglutide. Insurance coverage is increasingly common for both in T2D, less consistent for obesity, and expanding for tirzepatide post-OSA approval. Both are widely covered for established cardiovascular disease (semaglutide post-SELECT) and for sleep apnea (tirzepatide post-SURMOUNT-OSA). Compounded versions of both drugs proliferated during the 2023-2024 shortages but are now restricted under the FDA "essentially a copy" doctrine; access varies state-by-state. Both carry boxed thyroid C-cell warnings and contraindications in MEN-2 and personal/family medullary thyroid cancer. Patents on Wegovy/Ozempic begin to expire post-2031; on Mounjaro/Zepbound post-2032. Both are Schedule-unscheduled, prescription-only. Off-label use in non-obese populations or for cosmetic weight loss is contested by payers and increasingly by state medical boards. See the FDA Wegovy label and FDA Zepbound label for current prescribing information.
Related on Peptide Story
- Semaglutide fact box
- Tirzepatide fact box
- Weight Loss pillar guide
- Tapering off GLP-1s without rebound
- GLP-1 muscle preservation
References
- Aronne LJ, Horn DB, le Roux CW, et al. 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
- Frias JP, Davies MJ, Rosenstock J, et al. 2021. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. PMID 34170647
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PMID 35658024
- Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131
- Aronne LJ, Sattar N, Horn DB, et al. 2024. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. PMID 38078870
Semaglutide — community signal
Recent posts and videos mentioning Semaglutide from the cron-ingested Reddit + Bluesky pipelines and the curated /experts directory. Not endorsement — directional context only.
- r/Semaglutide· u/ohmymadeline2587 · 1h ago
One month update
A little background. 39F. Mom of 4. After 1st baby I lost all the weight doing CrossFit. 2nd baby took me 3 years to lose the weight doing Beach Body workouts and keto. Thought I was done having kids. Surprise baby #3. Gained 90lbs. Lost about 40 lbs when surprise #4. Gained another 90lbs. 3.5 years later and I'm sitting at 80lbs yet of baby weight. Last summer I decided to make a change and started running. Did the couch to 5k program. Then decided to sign up for a 10k. Trained for and ran that. Then my sister in law convinced me to sign up for a 1/2 marathon with her. Trained for and ran that. As accomplished and proud of myself as I am, I still can't look at and appreciate any of my race/post race pictures. In 6 months of running and training I bounced around the same +/- 5lbs and my clothes never got any looser. It was kinda depressing to put in so much work and not see the results I was hoping for. Then after my race I stopped running as long/as frequently and started to see the scale creep back up. Decided to look into GLP-1. Put myself first and used some of our tax return to purchase semaglutide. Started 1 month ago. SW: 210 lbs 5'7" 39f. CW: 200.4lbs Down 19.5 inches too! Including 5 in the bust, 4 in the waist, and 3 in the hips. Started at a very low dose 0.1 and am now up to 0.4. Had some headaches and mild nausea in the beginning but nothing too bad. Working out 4-5 days a week, plus I walk an average of 4-6 miles at work 4x/week. Eating around 1600 calories and drink about 7 owalas/day (always been a big water drinker). I'm so happy I made the decision to start on a sema. It finally gave my body that jumpstart it needed and to put in the work AND see the scale go down has been such a great feeling. Looking forward to month 2!   submitted by   /u/ohmymadeline2587 [link]   [comments]
- r/Semaglutide· u/pfassina · 1h ago
5 days on Foundayo
I’ve been 5 days on foundayo, which is a new semaglutide medication in pill form. This is my first experience with GLP-1 medicines, and wanted to get some pointers from the community to make this a smooth ride. So far I haven’t noticed any strong side effects, but I’ve noticed a few changes: I will easily feel fool after any meal. Having a bowl of Greek yogurt with granola and chia will make me feel like I had a big lunch with seconds. I’m burping a little more than usual. Since I’m feeling full all the time, I don’t even want to eat anything else between meals. Last couple of nights I had a burning sensation in the stomach while lying in bad. It was manageable, but not very comfortable. I had one pulled pork slider with one serving of potato salad for dinner at 6:30 pm, and was lying in bad at 10 pm. I’m on the starter dose, no nausea, and no significant changes to bowl movements. I guess all of this is normal and expected. Any tips on reducing the burning sensation at night?   submitted by   /u/pfassina [link]   [comments]
- r/Retatrutide· u/Alive_Site_3071 · 2h ago
Unpopular Opinion about Reta starting dose when transitioning from 15 mg Tirzepatide
**Disclaimer: This is not my opinion, I'm still researching and reading to decide how I will proceed. I got the feedback below from search/*ai* when asking for a hypothetical pharmocology opinion on this. I wanted to share here for your opinions and discussion on how your own experiences confirm or deny what it says. I haven't decided yet how I will proceed with the dosing for myself. Hypothetical feedback: Why you wouldn't start at the intro dose: Retatrutide is a triple agonist (GIP/GLP-1/glucagon receptor), while tirzepatide is a dual agonist (GIP/GLP-1). Someone already on 15 mg tirzepatide, the highest dose, has significant receptor adaptation to GIP and GLP-1 signaling. Starting them at the lowest retatrutide dose (0.5 mg) would be a massive step down in receptor activation, likely leading to the LOSS of appetite suppression , loss of blood sugar control, and loss of weight management progress. This mirrors the semaglutide-to-tirzepatide. Clinicians recognize that receptor tolerance/adaptation carries over between drugs sharing the same mechanism, so they bridge patients at a comparable activity level. Starting dose reasoning: Based on the phase 2 trial data for retatrutide, the efficacious doses ranged from 4 mg up to 12 mg. A clinician transitioning someone from max-dose tirzepatide would likely reason as follows: The GIP/GLP-1 component at around 8–12 mg retatrutide is roughly comparable in potency to higher-dose tirzepatide. So a reasonable starting point might be somewhere in the **8 mg range**, with titration up to 12 mg based on tolerability and response. **The glucagon receptor component is the wildcard.*\ * The patient has zero adaptation to glucagon receptor agonism, which is the novel third mechanism in retatrutide. That component can cause nausea and GI effects on its own. This might argue for a slightly more conservative start — perhaps **6–8 mg** — to let the body adjust to the glucagon piece, even though the GIP/GLP-1 tolerance is already established. **Bottom line hypothetically:** A thoughtful clinician would probably land around 8 mg as a starting dose, titrating up over a few weeks to 12 mg, watching GI tolerability closely because of the new glucagon agonism the patient hasn't been exposed to before. This is just the pharmacological reasoning that would likely apply. My thoughts: INTERESTING 😫 That's seems like a very high start to me😫 but I have no opinion about it yet. We will see!   submitted by   /u/Alive_Site_3071 [link]   [comments]
No Bluesky posts mentioning Semaglutide in our index yet — the Bluesky cron pulls every four hours.
No curated experts have Semaglutide tagged in their peptideAreas yet.
No YouTube videos mentioning Semaglutide in our index yet. The YouTube RSS cron pulls every 6 hours.
Tirzepatide — community signal
Recent posts and videos mentioning Tirzepatide from the cron-ingested Reddit + Bluesky pipelines and the curated /experts directory. Not endorsement — directional context only.
- r/Retatrutide· u/Alive_Site_3071 · 2h ago
Unpopular Opinion about Reta starting dose when transitioning from 15 mg Tirzepatide
**Disclaimer: This is not my opinion, I'm still researching and reading to decide how I will proceed. I got the feedback below from search/*ai* when asking for a hypothetical pharmocology opinion on this. I wanted to share here for your opinions and discussion on how your own experiences confirm or deny what it says. I haven't decided yet how I will proceed with the dosing for myself. Hypothetical feedback: Why you wouldn't start at the intro dose: Retatrutide is a triple agonist (GIP/GLP-1/glucagon receptor), while tirzepatide is a dual agonist (GIP/GLP-1). Someone already on 15 mg tirzepatide, the highest dose, has significant receptor adaptation to GIP and GLP-1 signaling. Starting them at the lowest retatrutide dose (0.5 mg) would be a massive step down in receptor activation, likely leading to the LOSS of appetite suppression , loss of blood sugar control, and loss of weight management progress. This mirrors the semaglutide-to-tirzepatide. Clinicians recognize that receptor tolerance/adaptation carries over between drugs sharing the same mechanism, so they bridge patients at a comparable activity level. Starting dose reasoning: Based on the phase 2 trial data for retatrutide, the efficacious doses ranged from 4 mg up to 12 mg. A clinician transitioning someone from max-dose tirzepatide would likely reason as follows: The GIP/GLP-1 component at around 8–12 mg retatrutide is roughly comparable in potency to higher-dose tirzepatide. So a reasonable starting point might be somewhere in the **8 mg range**, with titration up to 12 mg based on tolerability and response. **The glucagon receptor component is the wildcard.*\ * The patient has zero adaptation to glucagon receptor agonism, which is the novel third mechanism in retatrutide. That component can cause nausea and GI effects on its own. This might argue for a slightly more conservative start — perhaps **6–8 mg** — to let the body adjust to the glucagon piece, even though the GIP/GLP-1 tolerance is already established. **Bottom line hypothetically:** A thoughtful clinician would probably land around 8 mg as a starting dose, titrating up over a few weeks to 12 mg, watching GI tolerability closely because of the new glucagon agonism the patient hasn't been exposed to before. This is just the pharmacological reasoning that would likely apply. My thoughts: INTERESTING 😫 That's seems like a very high start to me😫 but I have no opinion about it yet. We will see!   submitted by   /u/Alive_Site_3071 [link]   [comments]
- r/Retatrutide· u/slovakembassy · 9h ago
should I try tirzepatide instead?
I've been taking reta for 5 months now, on and off. For the first few months it was consistent weekly, then I've taken breaks when the symptoms got too bad. I've comprehensively experimented between 2-5mg doses after having gotten my body used to it at the start. Consistently, I experience increased food noise than before reta, mainly for sugary foods, but also just never feeling full for long. I experimented taking 5mg and that had me unable to eat anything, but then my body adjusted and the food noise immediately came back. The issue with this is that I thought I was supposed to save money on food on a GLP 1, but am now spending even more lol. The most disruptive thing about it is my bad sleep- I wake up more times in the night than usual and always awaken between 5-6am and can't fall back asleep, regardless of how exhausted I am. Another two side effects I have are constant diarrhea and also alcohol doesn't work AT ALL. However, on it, and even when I haven't taken it for weeks, I am able to maintain a low weight I couldn't even achieve when I was doing OMAD and carnivore or keto and looked 'snatched'. That's fucking awesome lol... That's why I will never go above 4mg now, cos the nausea and not being able to eat (not to mention the expense of buying so many vials) seems to have no purposes if I can eat all the cake in the world and still be a size 2. Anyone with experience with both tirz and reta and has had similar symptoms on reta able to give me any pointers? Thanksss   submitted by   /u/slovakembassy [link]   [comments]
- r/Semaglutide· u/a901501 · 9h ago
VLS tirzepatide 20 mg
Has anyone got any experience using this pen? I purchased through a friend who had been using. I want to know if anyone else has any experience with this pen? I’ve verified it on the website.   submitted by   /u/a901501 [link]   [comments]
No Bluesky posts mentioning Tirzepatide in our index yet — the Bluesky cron pulls every four hours.
No curated experts have Tirzepatide tagged in their peptideAreas yet.
No YouTube videos mentioning Tirzepatide in our index yet. The YouTube RSS cron pulls every 6 hours.
Community Notes
0 approved · moderated
Structured notes from readers — context, citations, corrections, and first-hand experience. Every note is moderated before it appears. Notes do not replace medical review; they supplement it.
No approved notes yet.
Know something that should be on this page? A citation, clarification, or dispute? Sign in and submit the first note.
Submission interface coming in Phase 2. For now, notes are authored in Studio. See the Community Guidelines for moderation criteria.